Dylan Cease’s September Activation Does Not Settle 2027

Dylan Cease is off the injured list. That is a transaction, not a verdict on 2027.

Toronto activated him on September 28, after its final game of a 79-83 season. The move belongs in the record. So does the September 23 move that put him on the 15-day injured list, retroactive to September 20, with right shoulder inflammation.

Recent reporting says an MRI showed no structural damage. Good. The same reporting says his four-seamer averaged below 95 mph in multiple recent starts, its lowest sustained levels of his MLB career.

The Blue Jays should treat those facts as different kinds of information. One offers reassurance about a reported medical finding. The other raises a performance question that an activation alone cannot answer.

An available name is not an answered question

The temptation is obvious. Put Cease back on the active roster, see his name among the September 28 activations and move his shoulder to the resolved column.

That would be too convenient.

There is no need to declare a disaster. According to the reporting, the MRI found no structural damage. There is also no basis here to declare that the velocity concern has passed. No post-activation start appears in the supplied game record; Toronto’s last game was Sunday, before the move.

Nor should anyone pretend to know exactly why the reported dip happened. Shoulder inflammation and lower reported velocity appear in the same story. That does not establish a precise cause, a recovery timetable or what Cease will throw like in 2027.

The responsible stance is uncertainty, not panic. For a club making pitching decisions, uncertainty still has to count.

Sunday’s win cannot serve as evidence for Cease

The Blue Jays ended their season by beating Cincinnati 5-1. Max Scherzer worked 7.0 innings, allowed 1 earned run and struck out 7. Brandon Valenzuela homered in the second, and Charles McAdoo added a homer in the eighth.

That was a good afternoon. It was also someone else’s start.

Scherzer’s outing tells Toronto something about Sunday. It tells the club nothing about whether Cease’s reported velocity dip will persist next year. The same goes for winning 2 of 3 against the Reds. Those games happened, and the wins count. They cannot supply an observation of Cease after his activation.

This distinction sounds painfully literal because it is. Fans and front offices alike want the last image of a season to do more work than it can. A tidy 5-1 finish feels like an invitation to file away the problems that did not appear on that day’s scorecard.

Cease’s shoulder question was not on that scorecard. That is precisely why the score cannot settle it.

---

Make the 2027 projection earn its confidence

The Blue Jays do not have to decide today that Cease will struggle next year. They do have to resist treating his expected return as proof of what his performance will be.

Those are different decisions. One leaves room for encouraging information. The other assumes the information has already arrived.

Before Toronto builds a pitching plan around a particular version of Cease, it needs evidence that speaks to both concerns: how his shoulder is doing and what his fastball looks like over time. A roster entry is not that evidence. A reported MRI result, reassuring as it is, does not measure future velocity.

If the answers are encouraging, excellent. The point is to let those answers change the plan rather than write the plan as though they are known now.

This is especially important after a fifth-place finish. A 79-83 club cannot afford to turn an open question into a comfortable assumption just because the uncomfortable version complicates its offseason work.

Reassurance has limits

Cease’s activation is preferable to seeing his name remain on the injured list. Nobody needs to argue otherwise to take the shoulder concern seriously.

But the reported velocity dip deserves the same honesty as the reassuring MRI report. Neither should be edited out to make the story simpler.

The Blue Jays’ position should be clear: welcome the September 28 move, ask what it actually establishes and refuse to promote it into a guarantee about 2027.

A line on a transaction page can close an injured-list stint. It cannot finish a pitching evaluation.